Biotech Values

[DewDiligence]

AGN addendum: With 15% of sales and rapid growth in emerging markets, particularly from self-pay products such as Botox cosmetic, AGN is a play on The Global Demographic Tailwind (#board-15427) without the patent-cliff baggage of Big Pharma. AGN’s P/E ratio is much higher than Big Pharma companies, but the company’s product portfolio and near-flawless execution justify a relatively high P/E, IMO.